Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC, which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
The approval marks a critical step for Regentis as it moves toward broader market availability. The improved manufacturing efficiency could lower production costs and increase supply, potentially making the treatment more accessible to patients suffering from cartilage damage. With no off-the-shelf treatment currently available for the estimated 470,000 cases of knee cartilage repair annually in the U.S., GelrinC aims to fill a significant unmet medical need.
The implications of this announcement extend beyond Regentis. For patients, a scalable and safer manufacturing process could lead to broader adoption of regenerative medicine solutions for joint health, potentially reducing the need for more invasive surgeries like knee replacements. For the orthopedic industry, GelrinC represents a shift toward cell-free, off-the-shelf implants that simplify procedures and reduce variability associated with cell-based therapies.
Investors should note the forward-looking statements in the company’s announcement, which caution that actual results may differ materially due to risks and uncertainties. The full press release is available at https://ibn.fm/Ths4h, and additional updates can be found in the company’s newsroom at https://ibn.fm/RGNT.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process.
